A person's immune cells are engineered to hunt down aged cells
Drugs that kill aged cells (cells that have stopped dividing but will not die, and inflame their neighbours) hit many cell types at once. A sharper tool is to teach the immune system to find them: take a person's own T cells, the immune cells that kill infected cells, and fit them with a receptor for a protein that aged cells carry on their surface, the way cancer T-cell therapies are built. In 2020 a Memorial Sloan Kettering group did this in mice, using a surface protein called uPAR, and the engineered cells cleared aged cells from the livers of mice with liver scarring and improved the organ. A 2024 follow-up from the same group reported that one dose in young mice protected them into old age. Nothing of the kind has been tried in a person.
What would count
A person is given their own, or a donor's, immune cells engineered to recognise and kill aged cells, and afterwards has measurably fewer such cells in a tissue sample or a validated blood marker, in a peer-reviewed report. The animal rung is the same in a living animal. For the clinic rung: a regulator approves such a cell therapy for an age-related condition.
Who settles it: Peer-reviewed reports; the trial registry when a first person is treated; the regulator's approval record for the clinic rung.
Where it stands
Shown in animals. Reached 17 June 2020, on the record of doi.org. Next rung more than 20 years away, if ever.
When it reaches the clinic: the project's estimate
This is the one thing on this page that is a judgment rather than a record. The project's estimate of the year it reaches the clinic is 2046, no earlier than 2036 and no later than 2095; the model draws from that range every run, with the likely year the most probable draw. Set 16 October 2026, a first pass awaiting an outside review.
| Rung | No earlier than | Most likely | No later than | |
|---|---|---|---|---|
| First human | 2028 | 2031 | 2045 | |
| In clinical use | 2036 | 2046 | 2095 | feeds the year at the top |
Why. Engineered T cells for cancer took about twenty years from the first mouse results to the first approval in 2017, and they had a disease with a short path to a trial. For ageing the path runs through a first trial in a single condition (liver scarring is the one the mouse work points at), then an approval for it. The likely year assumes a first person is treated around 2030 and an approval for one condition follows in the mid 2040s; the earliest is the cancer-therapy pace with no setbacks; the latest allows for the surface-protein target proving unsafe in people, since uPAR also sits on some healthy cells.
Changes to this record
None since it was written on 16 October 2026. Every change to the stage or the estimate lands here with its date, the old value, the new one and the reason, and a change to the estimate never happens because a number looked wrong: it needs a dated reason and a source.
The last readings
- 17 October 2026 Quiet
Nothing in the window of the settler's kind: no registry entry, no first person treated, and no peer-reviewed report of engineered immune cells given to a person. A Medscape news piece dated 2026-10-14 reviews senolytic CAR T cells and says they remain preclinical with no approved therapy, which is press and confirms the stage rather than moving it. The same group's 2026 Cell paper (Zhang, Filliol, Sadelain, Lowe and colleagues, published 2026-03 by the repository address) turns uPAR-directed CAR T cells on solid tumours in mice, not on aged cells in a person, and is outside the window. The Cedars-Sinai PD-L2 paper (press release 2026-09-10) is about how aged cells hide from the immune system in mice and human samples, not about engineered cells.source 1, source 2, source 3, source 4
What the story so far says about it
No promise, self-experiment or logged paper names this one yet.
Notes
Related work, not the record here: a 2021 Japanese group reported a vaccine against a different surface protein (GPNMB) that cleared aged cells in mice. Engineered T cells cost hundreds of thousands of dollars per patient today, which is the main reason the horizon is far even if the biology holds up.